Last reviewed · How we verify
pentavalent antimony
At a glance
| Generic name | pentavalent antimony |
|---|---|
| Sponsor | Fundacion Nacional de Dermatologia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
- Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. (PHASE1, PHASE2)
- Intralesional Antimony for Bolivian Cutaneous Leishmaniasis (PHASE2)
- Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396 (PHASE2)
- Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis (PHASE2, PHASE3)
- Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
- Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients (PHASE4)
- Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pentavalent antimony CI brief — competitive landscape report
- pentavalent antimony updates RSS · CI watch RSS
- Fundacion Nacional de Dermatologia portfolio CI